Abstract
The present study was undertaken to characterize the mechanisms of the hemodynamic responses to microinjection of the selective μ-opioid receptor agonist [d-Ala2,MePhe4,Gly5-ol]enkephalin (DAMGO) into the paraventricular nucleus of the hypothalamus, in conscious rats chronically instrumented with pulsed Doppler flow probes. We found that i.v. pretreatment with phentolamine had no effect on the tachycardia elicited by DAMGO (1 nmol); however, the pressor response was reversed to a state of hypotension, the renal and superior mesenteric vasoconstrictions were attenuated and the hindquarter vasodilation was potentiated. In the presence of propranolol, the pressor response and renal vasoconstriction were unchanged, whereas the superior mesenteric vasoconstriction was reduced and the hindquarter vasodilation was abolished. Moreover, in those animals we observed bradycardia followed by tachycardia. Combined i.v. pretreatment with phentolamine and propranolol abolished the pressor and heart rate responses to DAMGO but had no effect on the renal and superior mesenteric vasoconstrictions, although the hindquarter vasodilation was reduced. Intravenous pretreatment with a vasopressin V1receptor antagonist or captopril had no effect on the cardiovascular responses to DAMGO. Together, these results indicate that the hypertension observed after injection of DAMGO into the paraventricular nucleus of the hypothalamus was secondary to alphaadrenoceptor-mediated vasoconstrictions in renal and superior mesenteric vascular beds and to betaadrenoceptor-mediated vasodilation in the hindquarter vascular bed, whereas the involvement of circulating vasopressin or angiotensin seems less obvious from the present findings. However, we cannot exclude the possibility that nonadrenergic, nonvasopressinergic and nonangiotensinergic vasoconstrictor mechanisms were acting in the renal and superior mesenteric vascular beds.
Footnotes
-
Send reprint requests to: Dr. Hélène Bachelard, Unité de Recherche sur l’Hypertension, Centre de Recherche du CHUL, 2705 boul. Laurier, Ste-Foy, Québec, G1V 4G2 Canada.
-
↵1 This work was supported by grants from the Heart and Stroke Foundation of Canada, the Natural Sciences and Engineering Research Council of Canada and the Fonds de la Recherche en Santédu Québec. H.B. is a Chercheur-Boursier of the Heart and Stroke Foundation of Canada.
- Abbreviations:
- aCSF
- artificial cerebrospinal fluid
- DAMGO
- [d-Ala2,MePhe4,Gly5-ol]enkephalin
- PVN
- paraventricular nucleus of the hypothalamus
- Received March 19, 1996.
- Accepted September 16, 1996.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|